UA102874C2 - Застосування рацемату піноцембрину у приготуванні лікарського препарату для лікування удару - Google Patents

Застосування рацемату піноцембрину у приготуванні лікарського препарату для лікування удару

Info

Publication number
UA102874C2
UA102874C2 UAA201108565A UAA201108565A UA102874C2 UA 102874 C2 UA102874 C2 UA 102874C2 UA A201108565 A UAA201108565 A UA A201108565A UA A201108565 A UAA201108565 A UA A201108565A UA 102874 C2 UA102874 C2 UA 102874C2
Authority
UA
Ukraine
Prior art keywords
pinocembrin
racemates
preparing medicaments
treating stroke
stroke
Prior art date
Application number
UAA201108565A
Other languages
English (en)
Russian (ru)
Inventor
Ганьхуа Ду
Цзіньсюй Ван
Сун У
Ін Ши
Мей Гао
Іньгуй Лі
Янь Ці
Дунмінь Шень
Хунмей Гуан
Хайлі Лю
Жуй Лю
Сяолун Фен
Original Assignee
Цспц Чжунці Фармасьютікал Текнолоджі (Шицзячжуан) Ко., Лтд.
Інстітьют Оф Матєріа Мєдіка, Чайніз Акедемі Оф Медікал Сайєнсіз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цспц Чжунці Фармасьютікал Текнолоджі (Шицзячжуан) Ко., Лтд., Інстітьют Оф Матєріа Мєдіка, Чайніз Акедемі Оф Медікал Сайєнсіз filed Critical Цспц Чжунці Фармасьютікал Текнолоджі (Шицзячжуан) Ко., Лтд.
Publication of UA102874C2 publication Critical patent/UA102874C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Винахід стосується застосування рацемату піноцембрину, рацемату солі піноцембрину, рацемату попередника піноцембрину або рацемату гідрату піноцембрину у виробництві лікарського препарату для профілактики та лікування удару, зокрема гострого ішемічного удару.
UAA201108565A 2008-12-11 2009-12-10 Застосування рацемату піноцембрину у приготуванні лікарського препарату для лікування удару UA102874C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810185559 2008-12-11
PCT/CN2009/075456 WO2010066199A1 (zh) 2008-12-11 2009-12-10 松属素外消旋体在制备治疗脑卒中药物中的用途

Publications (1)

Publication Number Publication Date
UA102874C2 true UA102874C2 (uk) 2013-08-27

Family

ID=42242358

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201108565A UA102874C2 (uk) 2008-12-11 2009-12-10 Застосування рацемату піноцембрину у приготуванні лікарського препарату для лікування удару

Country Status (17)

Country Link
US (1) US20110245334A1 (uk)
EP (1) EP2377529A4 (uk)
JP (1) JP5770098B2 (uk)
KR (1) KR20110094136A (uk)
CN (1) CN102548626A (uk)
AP (1) AP2011005766A0 (uk)
AU (1) AU2009326715B2 (uk)
BR (1) BRPI0923242A8 (uk)
CA (1) CA2746457A1 (uk)
CU (1) CU20110130A7 (uk)
EA (1) EA022275B1 (uk)
IL (1) IL213440A0 (uk)
MX (1) MX2011006141A (uk)
SG (1) SG172072A1 (uk)
UA (1) UA102874C2 (uk)
WO (1) WO2010066199A1 (uk)
ZA (1) ZA201105037B (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
WO2017165508A1 (en) 2016-03-24 2017-09-28 Im Therapeutics Methods of treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant
UY26816A1 (es) * 2001-07-04 2003-04-30 Horacio Heinzen Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo.
CN1285334C (zh) * 2004-05-12 2006-11-22 中国医学科学院药物研究所 生松素在制备防治神经细胞损伤相关疾病药物中的应用
CN1879656B (zh) * 2006-04-27 2010-04-21 魏春华 固体水溶性蜂胶组合物及其制备方法
CN101537188B (zh) * 2007-03-21 2012-07-18 中国医学科学院药物研究所 松属素环糊精或环糊精衍生物包合物
CN101307044B (zh) * 2007-05-16 2012-07-04 中国医学科学院药物研究所 生松素化合物两种晶型和制备方法及在疾病治疗中的应用
US20090232782A1 (en) * 2008-03-14 2009-09-17 Yu-Show Fu Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells
BRPI0823254A2 (pt) * 2008-11-11 2015-06-23 Inst Materia Medica Cams Complexos de inclusão de pinocembrina com ciclodextrina ou seus derivados

Also Published As

Publication number Publication date
MX2011006141A (es) 2011-09-21
KR20110094136A (ko) 2011-08-19
IL213440A0 (en) 2011-07-31
AU2009326715A1 (en) 2011-07-14
US20110245334A1 (en) 2011-10-06
EA201170776A1 (ru) 2011-12-30
SG172072A1 (en) 2011-07-28
CA2746457A1 (en) 2010-06-17
BRPI0923242A2 (pt) 2016-01-26
BRPI0923242A8 (pt) 2016-09-13
EA022275B1 (ru) 2015-12-30
JP2012511518A (ja) 2012-05-24
ZA201105037B (en) 2012-09-26
AU2009326715B2 (en) 2015-12-03
JP5770098B2 (ja) 2015-08-26
EP2377529A1 (en) 2011-10-19
EP2377529A4 (en) 2013-05-22
CN102548626A (zh) 2012-07-04
AP2011005766A0 (en) 2011-06-30
WO2010066199A1 (zh) 2010-06-17
CU20110130A7 (es) 2012-01-31

Similar Documents

Publication Publication Date Title
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
BR112012001372A2 (pt) comprimido, e, métodos para preparar um comprimido e para a profilaxia ou tratamento de hiperfosfatemia.
EA201490559A1 (ru) Композиция для лечения свища
BR112014012666A2 (pt) composição de revestimento marcada, artigo, método para preparar o artigo e método para autenticar uma composição
BRPI1007302A2 (pt) composto, inibidor da produção de colágeno, e, agente para tratar doenças associadas com a produção excessiva de colágeno
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
IN2014DN11078A (uk)
UA102874C2 (uk) Застосування рацемату піноцембрину у приготуванні лікарського препарату для лікування удару
HK1149012A1 (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
HK1149011A1 (en) Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments
SG178967A1 (en) Antimicrobial compositions and products
ATE502918T1 (de) Arylsulfonamide mit analgetischer wirkung
DOP2011000205A (es) Compuestos etanaminicos y su uso para tratar la depresion
NZ590913A (en) (2-aminomethylquinazolin-4-yl)-(4-methoxyphenyl)methylamine for treating or ameliorating neoplasm or cancer
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
AR076368A1 (es) Composicion para el tratamiento capilar
UA43017U (uk) Спосіб лікування хворих на хронічний поліпозний етмоїдит
UA80382U (en) 1-(para-methoxyphenyl)-2-(4,5,6,7-tetrahydro-3h-azepin-2-ylamino)-ethanon hydrochloride having positive inotropic effect
UA42271U (uk) Засіб для лікування глибокого карієсу
UA43018U (en) Method for immunocorrection of chronic polypous ethmoiditis
JO3117B1 (ar) استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين
TN2015000387A1 (en) Use of (RS)-S-cyclopropyl-S-(4-{[4-{[(lR, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2yl]amino}phenyl)sulphoximide for treatment of specific tumours